4.7 Article

Molecular Identification and Antifungal Susceptibility of Yeast Isolates Causing Fungemia Collected in a Population-Based Study in Spain in 2010 and 2011

期刊

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 58, 期 3, 页码 1529-1537

出版社

AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.02155-13

关键词

-

资金

  1. Astellas Pharma
  2. bioMerieux
  3. Gilead Sciences
  4. Merck Sharp and Dohme
  5. Pfizer
  6. Schering Plough
  7. Soria Melguizo SA
  8. Ferrer International
  9. European Union
  10. ALBAN program
  11. Spanish Agency for International Cooperation
  12. Spanish Ministry of Culture and Education
  13. Spanish Health Research Fund
  14. Instituto de Salud Carlos III
  15. Ramon Areces Foundation
  16. Mutua Madrile a Foundation
  17. MICOLAB
  18. Fundacion Mutua Madrilena
  19. Spanish Health Research Fund (FIS)
  20. Fondo de Investigacion Sanitaria (FIS) [MS09/00055, CD09/00230]
  21. Gilead
  22. MSD
  23. Astellas
  24. Fundacion SEIMC-GESIDA
  25. European Regional Development Fund (ERDF)
  26. Spanish Network for Research in Infectious Diseases [REIPI RD12/0015]

向作者/读者索取更多资源

We report the molecular identifications and antifungal susceptibilities of the isolates causing fungemia collected in the CANDIPOP population-based study conducted in 29 Spanish hospitals. A total of 781 isolates (from 767 patients, 14 of them having mixed fungemia) were collected. The species found most frequently were Candida albicans (44.6%), Candida parapsilosis (24.5%), Candida glabrata (13.2%), Candida tropicalis (7.6%), Candida krusei (1.9%), Candida guilliermondii (1.7%), and Candida lusitaniae (1.3%). Other Candida and non-Candida species accounted for approximately 5% of the isolates. The presence of cryptic species was low. Compared to findings of previous studies conducted in Spain, the frequency of C. glabrata has increased. Antifungal susceptibility testing was performed by using EUCAST and CLSI M27-A3 reference procedures; the two methods were comparable. The rate of fluconazole-susceptible isolates was 80%, which appears to be a decrease compared to findings of previous studies, explained mainly by the higher frequency of C. glabrata. Using the species-specific breakpoints and epidemiological cutoff values, the rate of voriconazole and posaconazole in vitro resistance was low (<2%). In the case of C. tropicalis, using the EUCAST procedure, the rate of azole resistance was around 20%. There was a correlation between the previous use of azoles and the presence of fluconazole-resistant isolates. Resistance to echinocandins was very rare (2%), and resistance to amphotericin B also was very uncommon. The sequencing of the hot spot (HS) regions from FKS1 or FKS2 genes in echinocandin-resistant isolates revealed previously described point mutations. The decrease in the susceptibility to fluconazole in Spanish isolates should be closely monitored in future studies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据